Most breast cancer patients are getting chemotherapy they don't need. That's the finding of a rigorous international clinical trial published this week and presented at the American Society of Clinical Oncology's annual meeting in Chicago.

The trial is called Optima. It's led by Prof. Rob Stein, a breast oncology professor at University College London. It followed more than 4,000 newly diagnosed breast cancer patients across the UK, Norway, Sweden, Australia, New Zealand, and Thailand.

What the Test Does

Scientists used a genomic test called Prosigna, which measures the activity of 50 genes involved in breast cancer growth. It produces a risk score predicting how likely a patient's cancer is to return.

Patients who scored low — two-thirds of trial participants — were treated with hormone therapy alone. No chemotherapy.

Their five-year survival rate: 93.7%.

The survival rate for patients who did receive chemotherapy: 94.9%.

A 1.2 percentage point difference separates the two groups. For that margin, thousands of women every year are subjected to hair loss, nausea, infertility, cognitive impairment, immune system damage, and in rare cases, leukemia.

This Isn't New — But It's Getting Bigger

This isn't the first study to ask this question. According to The Guardian, a separate U.S.-based trial called Tailorx — which used a different gene test called Oncotype DX, analyzing 21 tumor genes — reached similar conclusions years earlier.

Dr. Harold Burstein, an associate professor at Harvard Medical School, said of those findings: "Practically speaking, this means that thousands of women will be able to avoid chemotherapy, with all of its side effects, while still achieving excellent long-term outcomes."

The Tailorx trial looked at more than 10,000 women aged 18 to 75. It found that women with low recurrence scores didn't benefit from chemo at all. Only the 14% of women with the highest risk scores genuinely needed it.

The Optima trial, according to BBC News, represents the next major step — broader, more recent, and covering a different patient population, including women over 40 with early-stage breast cancer that had spread to nearby lymph nodes.

The Real-World Stakes

University College London told BBC News that more than 5,000 NHS patients a year could benefit from this approach in the UK alone.

Scale that globally. Breast cancer is the world's most common cancer. According to The Guardian's reporting on the Tailorx findings, roughly 123,000 women in the U.S. and 23,000 in the UK are diagnosed each year with the specific hormone-receptor-positive, HER2-negative form of the disease these tests target — which accounts for about half of all breast cancer cases.

If two-thirds of those patients are currently receiving unnecessary chemotherapy, the human cost is staggering. Not just in suffering, but in dollars. Chemotherapy is expensive. Every unnecessary treatment cycle is a waste of healthcare resources and a tax on patients' bodies.

What Mainstream Coverage Is Missing

BBC News and The Guardian both covered this responsibly on the clinical facts.

But one question goes largely unasked: Why has this taken so long?

The Tailorx data showing that large numbers of women don't need chemo was presented at the American Society of Clinical Oncology back in 2018 — nearly eight years ago. Prof. Arnie Purushotham, a senior clinical adviser at Cancer Research UK, called it groundbreaking at the time.

So why are we still talking about this as a future possibility rather than a current standard of care? Why are oncologists still defaulting to chemotherapy for patients who the science says don't need it?

The mainstream coverage treats this like a hopeful new discovery. It's not entirely new. It's a confirmation that the medical system has been slow to update its defaults.

What This Means for Patients

If you or someone you know has been diagnosed with early-stage, hormone-receptor-positive breast cancer, the Prosigna test and Oncotype DX tests exist right now. Ask your oncologist about them. Don't assume chemo is the only path because it's the default path.

Prof. Rob Stein told The Guardian: "Our findings show that many patients can safely avoid chemotherapy without compromising their outcomes."

That's the doctor leading the trial talking.

The Takeaway

Medicine progresses. But institutions — hospitals, insurers, treatment guidelines — move slow. Millions of women may be enduring chemotherapy not because the science demands it, but because the system hasn't caught up.

That's a failure worth examining.